Tuesday, December 13, 2022

PLGA from PolySciTech used in development of cell penetrating peptide decorated nanoparticles for pulmonary delivery to treat lung infection.

 

Utilizing systemic delivery methods to treat lung infections is associated with side effects due to poor delivery across cell barriers. Cell penetrating peptides (CPP) have a unique ability to cross cell membranes allowing for intracellular drug delivery. Researchers at University of Texas at Arlington and Southwestern Medical Center utilized PLGA (Cat# AP040) from PolySciTech Division of Akina, Inc. (www.polyscitech.com) to create nanoparticles and combined these with CPP to provide for inhalable nanoparticles which can enter lung epithelial cells and treat bacterial or viral diseases. This research holds promise to improve therapies against several lung diseases. Read more: Chintapula, Uday, Su Yang, Trinh Nguyen, Yang Li, Justyn Jaworski, He Dong, and Kytai T. Nguyen. "Supramolecular Peptide Nanofiber/PLGA Nanocomposites for Enhancing Pulmonary Drug Delivery." ACS Applied Materials & Interfaces (2022). https://pubs.acs.org/doi/abs/10.1021/acsami.2c15204

“Abstract: Effective drug delivery to pulmonary sites will benefit from the design and synthesis of novel drug delivery systems that can overcome various tissue and cellular barriers. Cell penetrating peptides (CPPs) have shown promise for intracellular delivery of various imaging probes and therapeutics. Although CPPs improve delivery efficacy to a certain extent, they still lack the scope of engineering to improve the payload capacity and protect the payload from the physiological environment in drug delivery applications. Inspired by recent advances of CPPs and CPP-functionalized nanoparticles, in this work, we demonstrate a novel nanocomposite consisting of fiber-forming supramolecular CPPs that are coated onto polylactic-glycolic acid (PLGA) nanoparticles to enhance pulmonary drug delivery. These nanocomposites show a threefold higher intracellular delivery of nanoparticles in various cells including primary lung epithelial cells, macrophages, and a 10-fold increase in endothelial cells compared to naked PLGA nanoparticles or a twofold increase compared to nanoparticles modified with traditional monomeric CPPs. Cell uptake studies suggest that nanocomposites likely enter cells through mixed macropinocytosis and passive energy-independent mechanisms, which is followed by endosomal escape within 24 h. Nanocomposites also showed potent mucus permeation. More importantly, freeze-drying and nebulizing formulated nanocomposite powder did not affect their physiochemical and biological activity, which further highlights the translative potential for use as a stable drug carrier for pulmonary drug delivery. We expect nanocomposites based on peptide nanofibers, and PLGA nanoparticles can be custom designed to encapsulate and deliver a wide range of therapeutics including nucleic acids, proteins, and small-molecule drugs when employed in inhalable systems to treat various pulmonary diseases.”

No comments: